Pharma market access consultancy WG Consulting has opened its first US office, in New York, and appointed Charlotta Norgaard to lead it.
The firm provides on-the-ground strategic support to US-based pharmaceutical companies across all stages of the drug commercialization process - including market access insights and solutions, and the communication of brand value to clinical and payer stakeholders.
Norgaard (pictured) joins from Stamford, CT-based QD Healthcare, where she created and led the market access division. She previously ran her own consulting business, and before that served as Director of Access Solutions for Quorum Consulting in San Francisco - in both she specialised in reimbursement, among other areas. Born and raised in Denmark, she began her healthcare career at Genentech in San Francisco.
WG’s CEO Claire Gillis explains the timing of the US launch with reference to the Supreme Court’s recent upholding of the Affordable Care Act: ‘pharmaceutical companies will face radical changes in every aspect of their environment - from growing cost control pressures to stricter payer demands to new physician practice dynamics. During this turbulent time for our US customers, we thought it was critical to offer local experts who can work hand in hand with them, guiding them safely through a volatile landscape. With WG's deep global experience, we can help our US clients leverage the lessons learned across Europe, so they can capitalize on the successes and avoid the mistakes of countries that have gone through similar transitions.’
She describes Norgaard as ‘the ideal partner for our American clients’.
WG Consulting is part of the ghg network and is online at www.wg-group.com